Drugs / SONOLISIB
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01408316 | Jul → Oct 2011 | — | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00726583 | Jun 2008 → Sep 2011 | cancer | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01616199 | Aug 2012 → Dec 2014 | — | Cascadian Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01252628 | Dec 2010 → Nov 2013 | colorectal carcinoma, head and neck squamous cell carcinoma | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01204099 | Sep 2010 → Dec 2013 | head and neck squamous cell carcinoma, non-small cell lung carcinoma | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01331083 | Sep 2011 → Jan 2015 | prostate cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01259869 | Apr 2011 → Oct 2014 | glioblastoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SONOLISIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL411907 ↗ |
| Known as | PX-866 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01204099 ↗ |
| Action | Inhibit | “targeted inhibitor of PI-3K” NCT00726583 ↗ |
| Modality | Small molecule | “PX-866, an oral PI3K inhibitor” PMID 25605819 ↗ Jan 2015 |
| Route | Oral | “given orally” NCT00726583 ↗ |